J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches
Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.
You may also be interested in...
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.
Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.